Background/Aim: Coronavirus-19 (COVID-19) pandemic outbreak is currently having a huge impact on medical resource allocation. Breast Cancer (BC) patients are concerned both with BC treatment and COVID-19. This study aimed to estimate the impact of anxiety among patients, caused by the spreading of COVID-19. Patients and Methods: Between the 16th of January and the 20th of March 2020, we retrospectively enrolled 160 patients. Eighty-two patients with a suspected breast lesion (SBL) were divided into two groups: PRE-COVID-19-SBL and POST-COVID-19-SBL. Seventy-eight BC patients were divided into PRE-COVID-19-BC and POST-COVID-19-BC. Patient characteristics including age, marital status, SBL/BC diameter, personal and family history of BC, clinical stage and molecular subtype were recorded. Procedure Refusal (PR) and Surgical Refusal (SR) were also recorded with their reason. Results: BC and SBL analysis showed no difference in pre-treatment characteristics (p>0.05). Both POST-COVID-19-SBL and POST-COVID-19-BC groups showed higher rates of PR and SR (p=0.0208, p=0.0065 respectively). Infection risk represented primary reason for refusal among POST-COVID-19 patients. Conclusion: COVID-19-related anxiety could affect patients' decisionmaking process. Since December 2019, the novel coronavirus (SARS-COV-2) has emerged as a highly contagious human pathogen. On March 20, 2020 more than 234000 cases were confirmed worldwide , with more than 9800 registered deaths (1). Following the initial outbreak in the Chinese Hubei Province on March 11, WHO has labelled the latest coronavirus disease COVID-19 (caused by SARS-COV-2) as a pandemic. The reported fatality rate is 4.2% globally (1, 2). Human to human transmission occurs through direct contact or air droplets (2) placing health care providers at a high risk due to the close proximity to potentially infected patients (3). Preliminary data of nationwide analysis in China demonstrated cancer as a risk factor for developing severe complications/disease course among COVID-19 patients (4, 5). Although further studies are required in order to accurately estimate the risk (6, 7) among patients who underwent chemotherapy or surgery in the months prior to the outbreak, the risk of developing severe conditions seems considerably higher compared to the general population (6). Breast Cancer (BC) is the most common neoplasm worldwide representing the primary cause of death due to neoplasms in Italy (5). A report published in 2017 stated that more than 50% of BC patients were older than 60 years (8). Therefore, due to the higher risk of adverse events in older patients, underlined in the preliminary data (9), it is essential to evaluate the risk of COVID-19 infection among these frail BC patients (10). Furthermore, during the COVID-19 outbreak, hospital resources are reallocated from elective and semi-elective procedures to meet the needs of COVID-19 patients in critical conditions (11). The subsequent scarcity of resources could potentially delay diagnostic evaluations and treatment of BC ...
Background/Aim: Coronavirus disease is spreading worldwide. Due to fast transmission and high fatality rate drastic emergency restrictions were issued. During the lockdown, only urgent medical services are guaranteed. All non-urgent services, as breast cancer (BC) screening, are temporarily suspended. The potential of breast cancer screening programs in increasing the survival rate and decreasing the mortality rate has been widely confirmed. Suspension could lead to worse outcomes for breast cancer patients. Our study aimed to analyse the data and provide estimates regarding the temporary BC screening suspension. Patients and Methods: Data regarding breast cancer and respective screening programs were achieved through literature research and analysis. Results: Considering three different scenarios with respect to the lockdown's impact on breast cancer screening, we estimate that approximately 10,000 patients could have a missed diagnosis during these 3 months. Considering a 6-month period, as suggested by the Imperial college model, the number of patients who will not receive a diagnosis will rise to 16,000. Conclusion: Breast cancer screening should be resumed as soon as possible in order to avoid further breast cancer missed diagnosis and reduce the impact of delayed diagnosis. The Coronavirus disease 2019 (Covid-19) pandemic is becoming incessant, having infected almost four million people worldwide (1). Based on the latest data, in Italy, more than 200,000 people are positive for SARS-COV-2 with a case fatality rate of up to 14% (2). Due to the fast human-to-human transmission and the high fatality rate, on 10 March 2020, the Italian Government, as did other countries, introduced drastic emergency restrictions. These extraordinary measures to limit viral transmission, include: cessation of most activities, quarantine and strict self-isolation (2). Accordingly, this emergency implies a total reorganization of the Health System, including temporary resource reallocation toward COVID-19 (3). Many hospitals are turning into COVID-19 specialized medical centers. During this transition phase, only urgent medical services are guaranteed while oncological procedures are suffering a significant slowdown (3). In this regard, the Breast Unit has been strongly affected by these restrictions as well, with a potential impact on women's health and quality of life (4). Every year, 3 million patients receive a cancer diagnosis worldwide. Breast cancer (BC) corresponds to 14% of cancer diagnoses and to 30% of cancers in women. In Italy, approximately 53,500 women receive a BC diagnosis every year (5). During the last years, there has been an improvement 3047 This article is freely accessible online.
Background/Aim: Despite the large amount of clinical data available of Coronavirus-19 (COVID-19), not many studies have been conducted about the psychological toll on Health Care Workers (HCWs). Patients and Methods: In this multicentric descriptive study, surveys were distributed among 4 different Breast Cancer Centers (BCC). BCCs were distinguished according to COVID-19 tertiary care hospital (COVID/No-COVID) and district prevalence (DP) (High vs. Low). DASS-21 score, PSS score and demographic data (age, sex, work) were evaluated. Results: A total of 51 HCWs were analyzed in the study. Age, work and sex did not demonstrate statistically significant values. Statistically significant distribution was found between DASS-21-stress score and COVID/No-COVID (p=0.043). No difference was found in the remaining DASS-21 and PSS scores, dividing the HCWs according to COVID-19-hospital and DP. Conclusion: Working in a COVID-19-hospital represents a factor that negatively affects psychosocial wellbeing. However, DP seems not to affect the psychosocial well-being of BCC HCWs. During the outbreak, psychological support for low risk HCWs should be provided regardless DP. The first case of atypical pneumonia previously named as Severe Acute Respiratory Syndrome Corona Virus 2 (COVID-19) was recorded in December 2019 in China. Italy has been the first European country to be involved in this outbreak. The national health care system (NHS) is currently reallocating resources from elective and semi-elective patients toward severe COVID-19 patients (1, 2). Italy has exceeded the cases recorded in China and unfortunately, up to now (May, 17th), 225,435 cases and 31908 deaths have been registered with still over 700 admitted to intensive care units (3). The Italian outbreak is mainly located in clusters along the north of Italy (Lombardia, Veneto and Emilia Romagna) and a low incidence in central and southern regions (1, 3, 4). In order to control COVID-19, resource reallocation eventually led to the creation of hospitals partially or totally dedicated to COVID-19 patients (COVID-hospital), therefore 1685 This article is freely accessible online.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.